The estimated Net Worth of Venture Partners Vi Co Inve... is at least $3.05 Milion dollars as of 5 September 2014. Venture Inve owns over 100,000 units of Chimerix Inc stock worth over $599,718 and over the last 10 years Venture sold CMRX stock worth over $2,454,000.
Venture has made over 1 trades of the Chimerix Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture sold 100,000 units of CMRX stock worth $2,454,000 on 5 September 2014.
The largest trade Venture's ever made was selling 100,000 units of Chimerix Inc stock on 5 September 2014 worth over $2,454,000. On average, Venture trades about 100,000 units every 0 days since 2014. As of 5 September 2014 Venture still owns at least 697,346 units of Chimerix Inc stock.
You can see the complete history of Venture Inve stock trades at the bottom of the page.
Venture's mailing address filed with the SEC is 400 SOUTH EL CAMINO REAL, SUITE 1200, , SAN MATEO, CA, 94402.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex oraz Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: